{"entity":{"id":"vaccine-plus-pd1","kind":"pairing","name":"Personalised neoantigen vaccine + PD-1 blockade","aka":[],"tldr":"The vaccine teaches the immune system what to hunt; PD-1 blockade stops the tumour from switching the hunters off.","summary":"This combination pairs Personalised neoantigen (mRNA) vaccines with Immune checkpoint inhibitors: the vaccine teaches the immune system what to hunt and PD-1 blockade stops the tumour switching the hunters off. The mechanism is that vaccine-primed T cells encounter PD-L1 in the tumour and in residual disease, and checkpoint blockade preserves their effector function, while the adjuvant setting offers low tumour burden and time to mount immunity. In Melanoma, Intismeran autogene plus Pembrolizumab reduced recurrence in a phase 2b study and the phase 3 INTerpath-001 (V940-001) trial was positive in August 2026. In Pancreatic ductal adenocarcinoma, Autogene cevumeran plus atezolizumab is the corresponding pairing, described in the Rojas 2023 paper.","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov NCT05933577: INTerpath-001 (V940-001)","url":"https://clinicaltrials.gov/study/NCT05933577"}],"tags":[],"related":[],"cancers":["melanoma","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["intismeran-autogene","pembrolizumab","autogene-cevumeran"],"companies":[],"institutions":[],"pathways":["pd1-checkpoint"],"terms":[],"trials":["interpath-001"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"neoantigen-mrna-vaccine","b":"checkpoint-inhibitor","rationale":"Vaccine-primed T cells encounter PD-L1 in the tumour and residual disease; checkpoint blockade preserves their effector function. Adjuvant setting gives low tumour burden and time to mount immunity.","evidence":"Phase 3 positive (melanoma).","pairingType":"combination"},"route":"/pairings/vaccine-plus-pd1/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/"},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"pathway":[{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"}],"trial":[{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"paper":[{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/"}]}}